Korean J Med.  2013 May;84(5):624-628.

Behavioral Intervention and Anti-Obesity Drug Therapy

• Kim MK

Abstract

Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. The U.S. Preventive Service Task Force (USPSTF) recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. Behavioral interventions can lead to a moderate weight loss and improvement in blood sugar and other risk factors for cardiovascular disease. Behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. The U.S. Food and Drug Administration approved lorcaserin and phentermine plus topiramate combination for treatment of obesity in 2012.

Keyword

Obesity; Behavioral intervention; Anti-obesity drug

MeSH Terms

Adult
Advisory Committees
Anti-Obesity Agents
Benzazepines
Blood Glucose
Body Mass Index
Cardiovascular Diseases
Diethylpropion
Fructose
Humans
Incidence
Korea
Lactones
Life Expectancy
Mass Screening
Mazindol
Morpholines
Obesity
Phentermine
Risk Factors
United States Food and Drug Administration
Weight Loss
Anti-Obesity Agents
Benzazepines
Blood Glucose
Diethylpropion
Fructose
Lactones
Mazindol
Morpholines
Phentermine